January 27th, 2007
Yesterday, I had a visit from one of my friends. My friend is a pharmacist. During our conversation, I told him that our country is changing. All the sudden he started to laugh. He said, you’re right; it is changing to the worst. Well this is not what I meant. Lots of young people believe that leaving the country and working in gulf is a better choice. Well for me I believe that it is not %100 true.
Let’s take for example the line of pharmacy. You either work in a pharmacy store or as a sales man or in some factory. I told him why don’t try to innovate something in pharmacy, for example try to create some research company or try to invent some sort of cure… you well probably laugh at me. But I believe nothing is impossible.
He answered me that the government is putting a lot of restrictions and the market is not stable at all. I told him this because you still think inside this small circle. Your business and dreams should go beyond the Jordanian market.
And this is what I meant by the country is changing. Because the world is changing, and the whole business models are changing. The most important things for success are innovation and flexibly to infiltrate regional markets. You can’t ignore what is happing around you. If you don’t reach them, they will reach you.
This is a long subject and maybe one day ill come back and blog about it more. But the other day I received this article from another friend and it was exactly what I was talking about. There is a change.
Jordanian firm buys German oncology company for 45 million dollars
dpa German Press Agency
Published: Tuesday January 23, 2007
Amman- Amman-based Hikma Pharmaceuticals has bought the
German oncology sales and marketing company Ribosepharm GmbH from
Ratiopharm GmbH for 45 million dollars, Hikma chairman and CEO Samih
Darwazeh said Tuesday in a statement.
“The acquisition of Ribosepharm provides us with an excellent
platform from which to enter the large and fast-growing oncology
market, which is forecast to become the second largest within the
pharmaceutical industry by 2010,” Darwazeh said.
“Ribosepharm has a strong position in Germany, one of the largest
European oncology markets, and significant distribution capabilities.
We will be able to draw on its experience in the field of oncology
and use its expertise to expand into other oncology markets in
Europe, as well as in the United States, the Middle East and North
Africa (MENA) region,” he added.
Ribosepharm is a well-established and successful oncology company,
specialising in the marketing and distribution of branded generic
injectable oncology products both to private practices and hospitals
in Germany, Darwazeh said.
Since floating on the London Stock Exchange 15 months ago, Hikma
has searched for acquisitions to expand outside the MENA region.
According to company officials, the firm was currently mulling
several other acquisitions, including in the Middle East region and
in firms focusing on the injectables business.
© 2006 - dpa German Press Agency